

References

I-263

1. Moore KN, Oza AM, Colombo N, et al. Phase III, randomized trial of mirvetuximab soravtansine versus chemotherapy in patients with platinum-resistant ovarian cancer: primary analysis of FORWARD I. *ANNONC*. 2021;32(6):P757-765.
2. Elahere™ (mirvetuximab soravtansine-gynx), injection for intravenous use [package insert]. ImmunoGen, Inc. Waltham, MA. Revised 11/2022.
3. Clinical Pharmacology™ Compendium. 2024. Tampa FL: Gold Standard, Inc. Mirvetuximab soravtansine-gynx.
4. Micromedex DrugDex Compendium®. 2024. Mirvetuximab soravtansine-gynx.
5. National Comprehensive Cancer Network (NCCN). NCCN Drugs and Biologics Compendium®. 2024. Mirvetuximab soravtansine-gynx.